Angiogenesis inhibitors: a new class of drugs

Cancer Biol Ther. Jul-Aug 2003;2(4 Suppl 1):S127-33.

Abstract

Angiogenesis inhibitors belong to a new class of drugs. Many of these drugs are in clinical trials to treat cancer, while others have recently received FDA approval. However, angiogenesis inhibitors operate by different mechanisms than conventional cytotoxic chemotherapies, and require different guidelines for their optimum use in animal models and in humans. Some of the more significant guidelines of antiangiogenic therapy are assembled in this chapter, and their scientific basis is discussed.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / classification
  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Antineoplastic Agents / pharmacology
  • Clinical Trials as Topic
  • Humans
  • Models, Biological
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neovascularization, Pathologic*
  • Time Factors

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents